Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Genie29jon Mar 16, 2023 12:16am
295 Views
Post# 35341687

If Shiseido, then the device

If Shiseido, then the device

Happy to see the company is now flush with funds for a while. I think we all owe Andrew and company a big thank you for their investments!

I think we can / should all agree at this point in time that Replicel really needs a positive outcome wity Shoseido. without it, I really don't see how they survive long enough to get the device into the market. If the Shiseido outcome is positive, they will have so much cash they will be able to expedite the device and get that going ASAP which were only further their growth.


So long story short, I think we are ultimately deeply dependent on Shiseido for any sort of positive outcome for the survival of the company and our shares/investment. 


Andrew is on a mission. He is passionate about a positive outcome and we owe a lot to him for keeping this company afloat to see this through. I truly feel if Shiseido didn't have a positive outcome from their trials of RCH01, then they would have walked by now... but they haven't and to to me this is indicative of a very positive outcome that will favor, Replicel, our shares/investments, and everyone on this planet that needs some sort of hair transplant.

Cheers to an awesome late spring/early summer of celebrations! Staying cautiously optimistic

<< Previous
Bullboard Posts
Next >>